Bromodomain Inhibitors

A compound of formula (I) or a pharmaceutically acceptable salt thereof,

• wherein
• R1 is C1-C3 alkyl;
• Y is N or C(RY) wherein RY is hydrogen or C1-C3 alkyl;
• m is 0, 1, 2, 3, or 4;
• R2 is G1A, —N(Ra)S(O)2Rb, —N(Ra)C(O)Rb, or —N(Ra)C(O)ORb;
• Ra, at each occurrence, is independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, or —(C2-C6 alkylenyl)-ORx wherein Rx is hydrogen, C1-C6 alkyl, or C1-C6 haloalkyl;
• Rb, at each occurrence, is independently C1-C6 alkyl, C2-C6 alkenyl, C1-C6 haloalkyl, G1B, or —(C1-C6 alkylenyl)-ORj;
• G1A is formula (i)
• wherein
• Z1 is C(O) or C(Re)(Rf);
• Z2 is a bond, O, —(C(Rg)(Rh)p—C(Rm)(Rn)— wherein the left end of the moiety is attached to Z1, or N(Ri) wherein Ri is hydrogen, C1-C3 alkyl, or cyclopropyl;
• wherein the cyclopropyl is optionally substituted with 1, 2, 3, or 4 independently selected Rs groups;
• p is 0 or 1;
• Rc, Rd, Re, Rf, Rg, Rh, Rm, and Rn, are each independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, or cyclopropyl;
• wherein the cyclopropyl, at each occurrence, is optionally substituted with 1, 2, 3, or 4 independently selected Rs groups;
• or
• Rc and Rm together with the carbon atoms to which they are attached, form a C3-C6 monocyclic cycloalkyl or a 4-6 membered monocyclic heterocycle;
• wherein the C3-C6 monocyclic cycloalkyl and the 4-6 membered monocyclic heterocycle are each optionally substituted with 1, 2, 3, or 4 independently selected Rs groups;
• or
• Rc and Ri together with the atoms to which they are attached, form a 4-6 membered monocyclic heterocycle;
• wherein the 4-6 membered monocyclic heterocycle is optionally substituted with 1, 2, 3, or 4 independently selected Rs groups;
• or
• Rc and Rd together with the carbon atoms to which they are attached, form a C3-C6 monocyclic cycloalkyl or a 4-6 membered monocyclic heterocycle;
• wherein the C3-C6 monocyclic cycloalkyl and the 4-6 membered monocyclic heterocycle are each optionally substituted with 1, 2, 3, or 4 independently selected Rs groups;
• G1B is oxetanyl, cyclopropyl, cyclobutyl, or cyclopentyl;
• wherein each G1B is optionally substituted with 1, 2, 3, or 4 Rt groups;
• wherein each Rt is independently halogen, C1-C6 alkyl, or C1-C6 haloalkyl;
• each R3 is independently C1-C3 alkyl, C1-C3 haloalkyl, halogen, —CN, —OR3a, —N(R3a)2, —C(O)R3a, cyclopropyl, or cyclobutyl;
• wherein each R3a is independently hydrogen, C1-C3 alkyl, or C1-C3 haloalkyl;
• R4 is phenyl or monocyclic heteroaryl;
• wherein each R4 is substituted with 2, 3, or 4 substituents wherein two of the substituents are independently selected from the group consisting of halogen, C1-C6 alkyl, and C1-C6 haloalkyl, and the optional substituents are independently selected from the group consisting of halogen, —CN, C1-C6 alkyl, C1-C6 haloalkyl, —S(C1-C6 alkyl), —S(O)2(C1-C6 alkyl), and —(C1-C6 alkylenyl)-OH;
• R5 is hydrogen, halogen, —CN, C1-C6 haloalkyl, or C1-C6 alkyl;
• R6 is —(C1-C3 alkylenyl)n-S(O)2—R6a or —N(R6b)—SO2—R6c;
• n is 0 or 1;
• R6a and R6c are each independently C1-C6 alkyl, C1-C6 haloalkyl, or cyclopropyl;
• wherein the cyclopropyl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of halogen, C1-C6 alkyl, and C1-C6 haloalkyl;
• R6b is hydrogen, C1-C6 alkyl, or C1-C6 haloalkyl;
• X1 and X2 are C(R7) or
• one of X1 and X2 is N and the other is C(R7);
• R7, at each occurrence, is independently hydrogen or halogen;
• Rs, at each occurrence, is independently C1-C6 alkyl, halogen, or C1-C6 haloalkyl;
• Rj, at each occurrence, is independently hydrogen, C1-C6 alkyl, or C1-C6 haloalkyl;
• and
• Rk, at each occurrence, is independently C1-C6 alkyl or C1-C6 haloalkyl.